Drug Profile
Pioglitazone/azilsartan
Alternative Names: Actos/TAK-536; AD 4883 536; Azilsartan/pioglitazone; Pioglitazone/TAK 536; TAK-536/pioglitazoneLatest Information Update: 26 Apr 2013
Price :
$50
*
At a glance
- Originator Takeda Global Research and Development Center
- Class Antihyperglycaemics; Benzimidazoles; Oxadiazoles; Thiazolidinediones
- Mechanism of Action Angiotensin type 1 receptor antagonists; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hypertension; Type 2 diabetes mellitus
Most Recent Events
- 01 Jun 2007 Discontinued - Phase-III for Type-2 diabetes mellitus (associated with hypertension) in USA (PO)
- 21 Jul 2006 Phase-III clinical trials in Hypertension in USA (PO)
- 21 Jul 2006 Phase-III clinical trials in Type-2 diabetes mellitus in USA (PO)